Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Saudi Arabia’s SFDA has approved Leqembi (lecanemab), the Kingdom’s first Alzheimer’s treatment. This innovative drug slows ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Leqembi is the second anti-amyloid drug to hit the market, but its predecessor was the controversial Aduhelm. The FDA granted accelerated approval to Aduhelm in 2021, despite a recommendation from ...

Because Leqembi is a Part B drug, not a more common Part D drug, many Medicare patients will owe 20 percent of the cost out-of-pocket. That adds up to more than $5,000 annually.

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to ...

Leqembi targets the amyloid protein that builds up in the form of plaques in the brains of people with Alzheimer's disease, said Dr. Judith Heidebrink, a neurologist at Michigan Medicine and ...

LEQEMBI is the only FDA- approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option. TOKYO and CAMBRIDGE, Mass., Jan ...

Alzheimer's drug Leqembi – a treatment proven to slow the clinical aspects of the progressive disease – could soon be available at several major U.S. health care systems. The Food and Drug ...

Alzheimer’s drug Leqembi received full approval from the U.S. Food and Drug Administration. An expert explains why this is a milestone in the treatment of the progressive disease.